Colestipol: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>David E. Volk
mNo edit summary
mNo edit summary
 
(3 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{subpages}}
{{subpages}}
[[Image:Colestipol.jpg|right|thumb|250px|{{#ifexist:Template:Colestipol.jpg/credit|{{Colestipol.jpg/credit}}<br/>|}}Components in colestipol resin.]]
{{Image|Colestipol.jpg|right|250px|Components in colestipol resin.}}


'''Colestipol''', sold under the brand names '''Cholestabyl''' and '''Colestid''', is a highly crosslinked insoluble basic anion exchange resin used to reduce cholesterol. It may also may reduce triglyceride levels.   
'''Colestipol''', sold under the brand names '''Cholestabyl''' and '''Colestid''', is a highly crosslinked insoluble basic anion exchange resin used to reduce cholesterol. It may also may reduce triglyceride levels.   


Colestipol hydrochloride binds [[bile acid]]s in the intestine forming a complex that is excreted in the feces, which blocks the reabsorption of the bile acids and their associated fats.  The diminished levels of bile acids leads to upregulation of the enzyme [[cholesterol 7-(alpha)-hydroxylase]], which increases the conversion of cholesterol to bile acids. The increased demand for cholesterol has the dual effect of increasing transcription and activity of the cholesterol biosynthetic enzyme [[HMG-CoA reductase]], and increasing the number of hepatic low-density lipoprotein (LDL) receptors. These compensatory effects result in increased clearance of LDL cholesterol (LDL-C) from the blood leading to decreased serum LDL levels.
Colestipol hydrochloride binds [[bile acid]]s in the intestine forming a complex that is excreted in the feces, which blocks the reabsorption of the bile acids and their associated fats.  The diminished levels of bile acids leads to upregulation of the enzyme [[cholesterol 7-(alpha)-hydroxylase]], which increases the conversion of cholesterol to bile acids. The increased demand for cholesterol has the dual effect of increasing transcription and activity of the cholesterol biosynthetic enzyme [[HMG-CoA reductase]], and increasing the number of hepatic low-density lipoprotein (LDL) receptors. These compensatory effects result in increased clearance of LDL cholesterol (LDL-C) from the blood leading to decreased serum LDL levels.
== Drug Interactions ==
Colestipol, a gastrointestinal binding agent, decreases the absorption and thus effectiveness of several drugs.  It decreases the anticoagulant effects of [[anisindione]], [[dicumarol]], [[acenocoumarol]] and [[warfarin]].  It also decreases the absorption of the [[thyroid hormone]]s [[levothyroxine]], [[liothyronine]], [[liotrix]] and [[thyroglobulin]]. Other drugs whose effects are lessened include [[digoxin]], [[fluvastatin]], [[hydrocortisone]], [[raloxifene]] and [[ursodeoxycholic acid]].
== External Links ==
{{CZMed}}[[Category:Suggestion Bot Tag]]

Latest revision as of 11:00, 30 July 2024

This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.
(CC) Image: David E. Volk
Components in colestipol resin.

Colestipol, sold under the brand names Cholestabyl and Colestid, is a highly crosslinked insoluble basic anion exchange resin used to reduce cholesterol. It may also may reduce triglyceride levels.

Colestipol hydrochloride binds bile acids in the intestine forming a complex that is excreted in the feces, which blocks the reabsorption of the bile acids and their associated fats. The diminished levels of bile acids leads to upregulation of the enzyme cholesterol 7-(alpha)-hydroxylase, which increases the conversion of cholesterol to bile acids. The increased demand for cholesterol has the dual effect of increasing transcription and activity of the cholesterol biosynthetic enzyme HMG-CoA reductase, and increasing the number of hepatic low-density lipoprotein (LDL) receptors. These compensatory effects result in increased clearance of LDL cholesterol (LDL-C) from the blood leading to decreased serum LDL levels.

Drug Interactions

Colestipol, a gastrointestinal binding agent, decreases the absorption and thus effectiveness of several drugs. It decreases the anticoagulant effects of anisindione, dicumarol, acenocoumarol and warfarin. It also decreases the absorption of the thyroid hormones levothyroxine, liothyronine, liotrix and thyroglobulin. Other drugs whose effects are lessened include digoxin, fluvastatin, hydrocortisone, raloxifene and ursodeoxycholic acid.

External Links

The most up-to-date information about Colestipol and other drugs can be found at the following sites.